Methyl Cinnamate (MC) Alleviates Free Fatty Acids (FFAs) Induced Lipid Accumulation Through the AMPK Pathway in HepG2 Cells
Yingda Fu,Guangbing Li,Zichen Feng,Jun Liu,Xiaoyu Wang,Tao Wang,Jun Liu
DOI: https://doi.org/10.2147/dmso.s449300
2024-03-08
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Yingda Fu, 1 Guangbing Li, 1, 2 Zichen Feng, 1 Jun Liu, 2 Xiaoyu Wang, 1 Tao Wang, 2 Jun Liu 1, 2 1 Department of Hepatobiliary Surgery and Center of Organ Transplantation, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, People's Republic of China; 2 Department of Hepatobiliary Surgery and Center of Organ Transplantation, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, People's Republic of China Correspondence: Jun Liu, Department of Hepatobiliary Surgery and Center of Organ Transplantation, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, People's Republic of China, Email Background: AMP-activated protein kinase (AMPK) plays a critical role in energy metabolism. Its activation leads to the phosphorylation of downstream proteins such as acetyl-CoA carboxylase (ACC) and sterol regulatory element-binding protein-1 (SREBP1), subsequently inhibiting de novo fatty acid synthesis, thereby reducing intracellular triglyceride accumulation. MC is a compound found in extracts from Zanthoxylum armatum DC plants. Research has shown that MC can inhibit the differentiation of 3T3-L1 adipocytes through the CAMKK2-AMPK pathway. However, the biological effect of MC in HepG2 cells remains unknown. Methods: In this study, we utilized HepG2 cells to establish a model of MAFLD through FFAs stimulation. We investigated the biological effects of MC on HepG2 cells and studied its impact on lipid metabolism. Small interfering RNA was employed to explore the mechanism by which MC activates AMPK. Finally, molecular docking was conducted, establishing a model of the interaction between AMPK and MC. Results: We observed that MC can alleviate triglyceride accumulation in HepG2 cells. We observed the elevated p-AMPK/AMPK, P-ACC/ ACC, and elevated CPT1a after treatment of MC in HepG2 cells. The interference of CAMKK2 mRNA did not impact the ability of MC to phosphorylate AMPK. Compound C attenuates the ability of MC to increase p-AMPK. Molecular docking results led us to hypothesize that MC directly interacts with AMPK, resulting in AMPK phosphorylation and improved lipid accumulation in HepG2 cells. Keywords: AMPK, CAMKK2, FFAs, HepG2, methyl cinnamate, MAFLD MAFLD is a progressive disease, encompassing a continuum of pathological stages including fatty liver, metabolic-associated steatohepatitis, fibrosis, and cirrhosis, which is the risk factor of HCC. The nomenclature of this disease was changed from NAFLD to MAFLD in 2020 for better diagnosis and severity evaluation. 1 In recent years, the incidence of MAFLD has been on the rise and is projected to reach 1.5 billion cases by 2030. 2,3 MAFLD is a multisystem disease and is associated with a higher risk of cardiovascular disease (CVD) 4,5 and chronic kidney disease (CKD). 6,7 Moreover, when there is an excess of fatty acids, the following oxidative stress and ER stress would initiate hepatocellular injury and further stimulate Kupffer cells, prompting the release of various inflammatory cytokines. 8,9 These inflammatory factors activate hepatic stellate cells, prompting their transformation into myofibroblast-like cells. 10 These cells secrete collagen, contributing to the development of fibrosis and cirrhosis. In advanced stages, including cirrhosis and HCC, liver transplantation would be necessary, 11 which strains the limited supply of available liver donors and poses a significant threat to patient survival and quality of life. Therefore, it is crucial to inhibit the progression of MAFLD and block the transition from fatty liver to liver fibrosis. AMPK is a trimeric protein comprising α, β, and γ subunits. The α subunit, when phosphorylated, becomes catalytically active and phosphorylates downstream targets, while the β and γ subunits are regulatory units that bind AMP/ADP/ATP, influencing conformation and impacting α subunit phosphorylation by upstream kinases. 12–15 AMPK activation is usually associated with phosphorylation at T183 in AMPKα1 and T172 in AMPKα2. 16 An increased AMP/ATP ratio helps AMPK maintain its phosphorylated state, this activation of AMPK triggers a metabolic shift from anabolic processes to catabolic processes. AMPK signaling pathway plays a crucial role in metabolism. ACC is involved in de novo fatty acid synthesis, and CPT1a is involved in fatty acid β-oxidation. Activated AMPK can phosphorylate ACC 17 to abolish its ability to produce malonyl-CoA, 18 which is an initial substrate for de novo fatty acid biosynthesis. Concurrently, malonyl CoA serves -Abstract Truncated-
endocrinology & metabolism